Research programme: RNAi therapeutics - Boston Biomedical

Drug Profile

Research programme: RNAi therapeutics - Boston Biomedical

Alternative Names: aiRNA therapeutics - Boston Biomedical; asiRNA therapeutics- AiRNA/Boston Biomedical; BBI 801

Latest Information Update: 14 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AiRNA Pharmaceuticals; Boston Biomedical
  • Developer Boston Biomedical
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 Sep 2016 Preclinical trials in Cancer in USA (Parenteral) before September 2016 (Boston Biomedical pipeline, September 2016)
  • 24 Apr 2012 Boston Biomedical has been acquired by Dainippon Sumitomo Pharma
  • 03 Dec 2009 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top